Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: an in-silico drug discovery approach

Publication date: Available online 2 September 2020Source: Journal of Molecular Graphics and ModellingAuthor(s): Ikechukwu Achilonu, Emmanuel Amarachi Iwuchukwu, Okechinyere Juliet Achilonu, Manuel Antonio Fernandes, Yasien Sayed

Source: Journal of Molecular Graphics and Modelling - September 3, 2020 Category: Molecular Biology Source Type: research